scispace - formally typeset
K

Kathleen R. Lamborn

Researcher at University of California, San Francisco

Publications -  268
Citations -  27324

Kathleen R. Lamborn is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Radioimmunotherapy. The author has an hindex of 88, co-authored 268 publications receiving 25597 citations. Previous affiliations of Kathleen R. Lamborn include Stanford University & Dartmouth College.

Papers
More filters
Journal ArticleDOI

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

TL;DR: The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Journal ArticleDOI

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

TL;DR: Improved outcome among adult patients with hemispheric LGG is predicted by greater EOR, and progression-free survival was predicted by log preoperative tumor volume and postoperative volume.
Journal ArticleDOI

Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme

TL;DR: It is found that the gene expression patterns in paired specimens from the same GBM invariably were more closely related to each other than to any other tumor, even when the paired specimens had strikingly divergent histologies.
Journal ArticleDOI

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

TL;DR: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels.
Journal ArticleDOI

Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis

TL;DR: Subgroup analyses indicated that inclusion of adjuvant chemotherapy provides an increase in survival, although that improvement tends to be minimal for patients over age 65, for patientsover age 40 with KPS less than 80, and for those treated with brachytherapy.